Program Advantages
First-in-class, broad indications (hematological and solid cancers. Breakthrough therapy designation to treat recurrent and refractory NHL)
Pipeline for Cancer
Programs
Target/MoA
Field
Rights
Indications
Discovery
IND-
Enabling
Phase I
Phase II
Pivotal
Phase II
Phase III
-
BEBT-908
- Dual PI3K/HDAC inhibito
- Cancer
- China
- DLBCL (3 rd line)
- PTCL and CTCL (3 rd line)
- FL, MZL, CLL/SCL (3 rd line)
- Advanced solid cancers (Breast cancer, lung cancer, colon cancer )
-
NDA
-
-
-
- 2022
- 2023
- 2023
- 2024
-
BEBT-209
- CDK4 selective CDK4/6 inhibitor
- Cancer
- Global
- HR+/HER2- breast cancer (plus fulvestrant)
- Combined with BEBT-908 for breast cancer resistant to CDK4/6 inhibitor and ET
- Triple negative breast cancer (plus chemotherapy)
-
Pivotal phase III trial
-
-
- 2023
- 2024
- 2025
-
BEBT-109
- Pan Mutant-EGFR inhibitor
- Cancer
- Global
- NSCLC with EGFR exon 20 insertion
- Combined with BEBT-908 for NSCLC, PD after 3rd generation TKI/Chemo
- 2023
- 2023
- 2024
- 2025
-
BEBT-260
- ChK1 inhibitor
- Cancer
- Global
- TP53 mutant solid cancers (Breast cancer,ovarian cancer. cervical cancer. lung cancer )
- 2024
Pipeline for Autoimmune and Metabolic Diseases
-
BEBT-305
- 2nd generation HSP90 inhibitor
- Autoimmune disease
- China
- Psoriasis
- 2025
-
BEBT-503
- Pan PPAR agonist
- Metabolic disease
- Global
- T2DM with NASH
- NASH
- 2026
- 2027
-
BEBT-808
- Oral Non-Peptide
GLP-1 Full Agonist
- Metabolic disease
- Global
- Diabetes and obesity
- Obesity
- 2027
- 2027
-
BEBT-809
- GPR75 pathway inhibitor
- Metabolic disease
- Global
- Obesity
- 2027
-
BEBT-508
- siRNA
- Metabolic disease
- Global
- NAFLD, NASH
-
BEBT-509
- siRNA
- Metabolic disease
- Global
- Obesity
-
-
Items
BEBT-908 PI3K/HDAC Inhibitor
- Indications
- Discovery
- Preclinical
- IND-
Enabling - Clinical Trials
- NDA预期
-
DLBCL (3 rd line)
-
关键验证II期
-
2022
-
PTCL and CTCL (3 rd line)
-
验证II期
-
2023
-
FL, MZL, CLL/SCL (3 rd line)
-
验证II期
-
2023
-
Advanced solid cancers (Breast cancer, lung cancer, colon cancer )
-
3个Ib/II期
-
2024
-
Items
-
-
Items
BEBT-209 CDK4/6 Inhibitor
- Indications
- Discovery
- Preclinical
- IND-
Enabling - Clinical Trials
- NDA预期
-
Alone or combination with BEBT-908 for advanced breast cancer resistant to CDK4/6 inhibitor and ET
-
IND评审中
-
2025
-
ER+/HER- breast cancer (plus letrozole, 1st line)
-
Ib期
-
2023
-
ER+/HER- breast cancer (plus letrozole,1st line)
-
完成II期
-
2024
Program Advantages
More CDK4 selective to reduce servere hematological toxicities of CDK6 inhibition. Showed better efficacy and safety than palbociclib in combination with fulvestrant in phase 1b/11 study.
-
Items
-
-
Items
BEBT-109 Pan Mutant-EGFR Inhibitor
- Indications
- Discovery
- Preclinical
- IND-
Enabling - Clinical Trials
- NDA预期
-
NSCLC with EGFR exon 20 insertion
-
关键II
-
2023
-
NSCLC with other uncommon EGFR mutations
-
2023
-
Combined with BEBT-908 for NSCLC, PD after 3rd generation TKI/Chemo
-
2024
-
NSCLC with EGFR T790 mutation (RCT
-
2025
Program Advantages
Highly potent pan mutant EGFR inhibitor with favorable PK property. Well tolerated and effective treatment in NSCLC patients with EGFR exon 20 insertion.
-
Items
-
-
Items
BEBT-260 ChK1 Inhibitor
- Indications
- Discovery
- Preclinical
- IND-
Enabling - Clinical Trials
- NDA预期
-
TP53 mutant solid cancers (Breast cancer,ovarian cancer. cervical cancer. lung cancer )
-
2024
Program Advantages
Highly selective and potent Chk1 inhibitor. Showed long half-life (50-60h)and it is wel l-tolerated in patients with solid cancer.
-
Items
-
-
Items
BEBT-305 HSP90 Inhibitor
- Indications
- Discovery
- Preclinical
- IND-
Enabling - Clinical Trials
- NDA预期
-
Psoriasis
-
2025
Program Advantages
First-in-class oral drug. Showed good safety and efficacy in patients with psoriasis in phase Ib clinical trial in Europe..
-
Items
-
-
Items
BEBT-503 Pan PPAR Agonist
- Indications
- Discovery
- Preclinical
- IND-
Enabling - Clinical Trials
- NDA预期
-
T2DM with NASH
-
中美双报
-
2026
-
NASH
-
中美双报
-
2027
Program Advantages
It is by far the most balanced and active pan-PPAR agonist.
-
Items
-
-
Items
BEBT-808 Oral Non-Peptide GLP-1 Full Agonist
- Indications
- Discovery
- Preclinical
- IND-
Enabling - Clinical Trials
- NDA预期
-
Diabetes
-
2027
-
Obesity
-
2027
Program Advantages
Highly potent non-peptide GLP-1R full agonist with more favarable PK profiles than danugIpron, an only full GLP-1R agonist in clinical development.
-
Items
-
-
Items
BEBT-809 GPR75R Inhibitor
- Indications
- Discovery
- Preclinical
- IND-
Enabling - Clinical Trials
- NDA预期
-
Obesity
-
2027
Program Advantages
First-in-class oral GPR75R inhibitor. Showed high bioavailability and good safety and efficacy preclinical studies
-
Items
Pipeline For Autoimmune And Metabolic Diseases
Copyright ©2018-2022 Guangzhou BeBetter Medicine Technology Co, LTD.粤ICP备18065301号